{"doi":"10.1208/s12248-021-00554-4","title":"Extracellular Vesicles in Oncology: from Immune Suppression to Immunotherapy","abstract":"<jats:title>Abstract</jats:title><jats:p>Exosomes are involved in cell-to-cell communication and play a crucial role in cellular physiology. The role of exosomes in cancer has been widely explored. Tumor cells have evolved and adapted to evade the immune response. The study of the immune system’s modulations in favor of rogue tumor cells led to the development of a novel immunotherapeutic strategy targeting the immune checkpoint proteins (ICPs). In clinical settings, the response to ICP therapy has been inconsistent and is difficult to predict. Quantitating the targeted ICPs through immunohistochemistry is one approach, but is not pragmatic in a clinical setting and is often not sensitive. Examining the molecules present in bodily fluids to determine ICP treatment response, “liquid biopsy” is a convenient alternative. The term “liquid biopsy” refers to circulating tumor cells (CTCs), extracellular vesicles (EVs), non-coding (nc) RNA, circulating tumor DNA (ctDNA), circulating free DNA (cfDNA), etc. EVs includes exosomes, microvesicles, and oncosomes. Herein, we focus on exosomes isolated from bodily fluids and their use in liquid biopsy. Due to their unique ability to transfer bioactive molecules and perturb the physiology of recipient cells, exosomes have garnered attention for their immune modulation role and as a resource to identify molecules associated with liquid biopsy–based diagnostic methods. In this review, we examine the putative role of exosomes and their cargo in influencing the immune system. We discuss the immune and tumor cells present in the tumor microenvironment (TME), and the exosomes derived from these cells to understand how they participate in creating the immune-suppressive TME. Additionally, use of exosomes in liquid biopsy–based methods to measure the treatment response elicited by immunotherapy is discussed. Finally, we describe how exosomes have been used to develop immune therapies, especially cell-free vaccines, for cancer treatment.</jats:p>","journal":"The AAPS Journal","year":2021,"id":32759,"datarank":1.144608342530233,"base_score":3.784189633918261,"endowment":3.784189633918261,"self_citation_contribution":0.5676284450877392,"citation_network_contribution":0.5769798974424938,"self_endowment_contribution":0.5676284450877392,"citer_contribution":0.5769798974424938,"corpus_percentile":null,"corpus_rank":null,"citation_count":43,"citer_count":42,"citers_with_citation_signal":35,"citers_with_endowment":35,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":172787,"name":"Shipra Rathore","orcid":null,"position":1,"is_corresponding":false},{"id":172788,"name":"Anupama Munshi","orcid":null,"position":2,"is_corresponding":false},{"id":172789,"name":"Rajagopal Ramesh","orcid":null,"position":3,"is_corresponding":false},{"id":172786,"name":"Akhil Srivastava","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":3.784189633918261,"endowment":3.784189633918261,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"33586060","pmcid":"PMC7882565","openalex_id":"https://openalex.org/W3129922343","authors":[],"funders":[{"funder_name":"BLRD VA","grant_id":"I01 BX003420","title":null},{"funder_name":"NCI NIH HHS","grant_id":"R01 CA167516","title":null},{"funder_name":"NCI NIH HHS","grant_id":"R01 CA233201","title":null},{"funder_name":"NCI NIH HHS","grant_id":"P30 CA225520","title":null},{"funder_name":"NIGMS NIH HHS","grant_id":"P20 GM103639","title":null},{"funder_name":"National Institutes of Health","grant_id":"5P20GM103639-08","title":"Mentoring Translational Cancer Research in Oklahoma"},{"funder_name":"National Institutes of Health","grant_id":"3P30CA225520-06S4","title":"Stephenson Cancer Center - Cancer Center Support Grant"},{"funder_name":"National Institutes of Health","grant_id":"5R01CA167516-03","title":"HuR Targeted Nanotherapy for Lung Cancer"},{"funder_name":"National Institutes of Health","grant_id":"1R01CA233201-01","title":"An improved IL-24 gene-based therapeutic for cancer"}],"total_grants":9,"fwci":2.768,"citation_percentile":0.91518689,"influential_citations":0,"citation_trend":[{"year":2021,"count":9},{"year":2022,"count":6},{"year":2023,"count":9},{"year":2024,"count":10},{"year":2025,"count":4},{"year":2026,"count":5}],"oa_status":"hybrid","license":"cc-by","oa_locations":[{"url":"https://link.springer.com/content/pdf/10.1208/s12248-021-00554-4.pdf","host_type":"journal"},{"url":"https://link.springer.com/content/pdf/10.1208/s12248-021-00554-4.pdf","host_type":"HYBRID"},{"url":"https://link.springer.com/content/pdf/10.1208/s12248-021-00554-4.pdf","host_type":"publisher"},{"url":"http://link.springer.com/content/pdf/10.1208/s12248-021-00554-4.pdf","host_type":"publisher"},{"url":"http://link.springer.com/article/10.1208/s12248-021-00554-4/fulltext.html","host_type":"publisher"},{"url":"https://doi.org/10.1208/s12248-021-00554-4","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/33586060","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7882565","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC7882565","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC7882565?pdf=render","host_type":"Europe_PMC"},{"url":"http://dx.doi.org/10.1208/s12248-021-00554-4","host_type":""},{"url":"https://dx.doi.org/10.1208/s12248-021-00554-4","host_type":""}],"fields_of_study":["Extracellular vesicles in disease","MicroRNA in disease regulation","Inflammatory Biomarkers in Disease Prognosis","Medicine","Biology","0301 basic medicine","0303 health sciences","03 medical and health sciences","Biomarkers, Tumor","Cancer Vaccines","Exosomes","Humans","Immune Checkpoint Inhibitors","Immune Checkpoint Proteins","Immunotherapy","Liquid Biopsy","Medical Oncology","Neoplasms","Neoplastic Cells, Circulating","Tumor Escape","Tumor Microenvironment"],"mesh_terms":["Liquid Biopsy","Immune Checkpoint Inhibitors","Immune Checkpoint Proteins","Humans","Immunotherapy","Medical Oncology","Neoplastic Cells, Circulating","Neoplasms","Biomarkers, Tumor","Tumor Escape","Cancer Vaccines","Exosomes","Tumor Microenvironment"],"keywords":["Microvesicles","Immune system","Liquid biopsy","Tumor microenvironment","Exosome","Immunotherapy","Cancer research","Biology","Cancer","Medicine","Immunology","microRNA","Internal medicine","Gene","Exosomes","Review Article","Immune Checkpoint Proteins","Medical Oncology","Neoplastic Cells, Circulating","Cancer Vaccines","Neoplasms","Biomarkers, Tumor","Humans","Tumor Escape","Immune Checkpoint Inhibitors"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-09T14:28:40.938342Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}